Up to now, six different SGLT2 inhibitors (SGLT2i) have been approved by the Food and Drug Administration (FDA) for the treatment of diabetes: dapagliflozin, empagliflozin, canagliflozin, ertugliflozin, sotagliflozin, and bexagliflozin. The gene discussed is SLC5A2; the disease is diabetes mellitus.